| Gene name: | TET1 |
| Aging type: | Prevent |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | H1299,H1975,H226,H441,Calu-6 |
| Gene ID: | 80312 |
| Category: | protein coding |
| Phenotype: | Lung cancer |
| Experimental category: | HL |
| PMID: | 30622117 |
| Experiment: | SA-β-gal activity assay//Cell morphological analysis//Colony formation assay//Crystal violet assay//Knockdown |
| Description: | TET1 knockdown significantly reduced proliferation of H1299, H1975, H226 and H441 cells at 120 h post-transfection by 63%, 40%, 24% and 21%, respectively, as determined using crystal violet assay. Furthermore, TET1 knockdown reduced anchorage independent growth of H1299, H226, and Calu6 lines as evident by 64%, 62% and 61% reduction in colony formation in soft agar, respectively.Cell morphology (enlarged size and flattened shape) suggested that these cells were undergoing cellular senescence and this was confirmed by analyzing the cells for β-galactosidase activity, a metabolic marker of senescence. Less than 1% of control cells showed detectable activity of this enzyme, while in the TET1 knockdown population, approximately 40% (H1299), 18% (H1975) and 6% (H226) of cells were β-galactosidase positive. |
| Target gene: | P53 |
| Official symbol(s): | P53 |
| R-AG-Target gene: | -- |
| Subcategory: | Binding to promoter |
| Target gene experiment: | CHIP//qRT-PCR |
| Target gene description: | As expected, no enrichment of p53 at its predicted binding site within the TET1 promoter region was detected in H1299 cells characterized by a p53-null mutation. Conversely, 23,800- and 13,500-fold enrichments of p53 at the TET1 promoter were found in the WT p53 cell lines A549 and H2228,respectively. Furthermore, p53 binding to the TET1 promoter was reduced ≥90% in p53-mutated cell lines (enrichment of 1,600-, 1,200-, 223- and 16- fold in H1975, Calu6, H1993 and SW900, respectively) and negatively correlated with overall TET1 expression.qRT-PCR analysis demonstrated that expression of p21 is elevated 6- to 70- fold in H1299 cells in a highly synergistic and dose-dependent manner by combined TET1 knockdown and chemotherapy treatment. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...